Robert Wasserman
Stock Analyst at Benchmark
(3.37)
# 916
Out of 5,182 analysts
119
Total ratings
49.54%
Success rate
3.38%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $86.02 | +10.44% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $65.36 | +37.70% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $231.27 | -4.87% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $64.62 | -14.89% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $5.25 | +614.29% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $54.19 | +38.41% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $8.29 | +80.94% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.46 | +310.96% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $37.86 | -7.55% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.15 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $21.38 | +40.32% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $2.87 | +74.22% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.03 | +49.44% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.62 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $117.60 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.41 | -9.30% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.98 | +3,255.70% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.33 | +3,118.88% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $177.25 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $469.71 | +23.48% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $86.02
Upside: +10.44%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $65.36
Upside: +37.70%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $231.27
Upside: -4.87%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $64.62
Upside: -14.89%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $5.25
Upside: +614.29%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $54.19
Upside: +38.41%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $8.29
Upside: +80.94%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.46
Upside: +310.96%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $37.86
Upside: -7.55%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.15
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $21.38
Upside: +40.32%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $2.87
Upside: +74.22%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.03
Upside: +49.44%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.62
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $117.60
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.41
Upside: -9.30%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.98
Upside: +3,255.70%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.33
Upside: +3,118.88%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $177.25
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $469.71
Upside: +23.48%